- All Targets
- Angiogenesis/Tyrosine Kinase
- Cell Cycle/Checkpoint
- HDAC
- Apoptosis
- PARP
- Aurora/Ksp
- MAPK
- PI3K/Akt/mTOR
- Hormone
- Integrase/CCR5
- Proteases/HSP90/HSP70
- Wnt/Hedgehog/Notch
- Jak/Stat
- Ca/cAMP/Lipid Signaling
- Neuro Signaling
- TGF-beta/Smad Signaling
- GPCR
- SCTR
- SSTR
- CRF receptor
- GCGR
- GHSR
- GRF-R
- Ghrelin receptor
- tachykinin NK1 receptor
- vasopressin receptor
- Angiotensin receptor
- CB1 receptor
- CB2 receptor
- OX receptor
- Beta-1 adrenergic receptor
- Smoothened (Smo)
- Alpha-1 receptor
- A2A adenosine receptor
- mGluR2/mGluR3
- PTGFR
- SGLT
- Opioid receptor
- Dopamine receptor
- Beta-2 adrenergic receptor
- Serotonin receptor
- Muscarinic receptor
- Ion channel
- Cytochrome P450
- Others
- Cancer
- Infection
- Endocrinology
- Metabolic Disease
- Inflammation
- Immunology
- Neurological Disease
- Cardiovascular Disease
Nilotinib (AMN-107)
(SynonymsTasigna
)Add to Favor
M.Wt: 529.52
Formula: C28H22F3N7O
Solubility: DMSO
Purity: >99%
Storage: at -20℃ 2 years
CAS No.: 641571-10-0
Price and Availability of Nilotinib (AMN-107):
Applications & Customer's Feedback of Nilotinib (AMN-107):
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. ------ Huang WC,Tsai CC,et al. FASEB J. 2011 Oct;25:3661-73.
Biological Activity of Nilotinib (AMN-107):
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.
AMN107 inhibited the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values <12 nM.
AMN107 was quantitatively via capture ELISA for its effect on cellular Bcr-Abl autophosphorylation activity and on Bcr-Abl-dependent cell proliferation. AMN107,IC50 =20–60 nM.[1]
The effects of AMN107 were compared with those of imatinib on imatinib-sensitive (KBM5 and KBM7) and imatinib-resistant CML cell lines (KBM5-STI571R1.0 and KBM7-STI571R1.0). Compared with the antiproliferative activity of imatinib , AMN107 was 43times more potent in KBM5 (IC50 of 11.3 versus 480.5 nM) and 60 times more potent in KBM7(IC50 of 4.3versus 259.0 nM) cells. IC50 for AMN107 and imatinib were 2,418.3 and 6,361.4 nM, respectively, in KBM5- STI571R1.0, and 97.2 and 2,497.3nM, respectively, in KBM7-STI571R1.0 cells.[2]
References on Nilotinib (AMN-107):
[1] Ellen Weisberg et al. Cancer Cell. 2005 February;17(2):129-141
[2] Mirna Golemovic et al. Clinical Cancer Research.2005 July; 11:4941
Src-bcr-AblWe give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) See Details
Find Multiple Products by Catalog Number
| Dongfeng Chen, The Rausing Lab |
| "Your product U0126(Cat.NO S1102) works well in our experiments. I hope I can get more excellent products from your company in future." |
| R.B. Cambridge |
| "I have used the chemical that I bought from you(Selleck,PTC-124) and it worked well.So we will eventually be ordering more." |
| Zhenghe John Wang Assistant Professor, Case Western Reserve University |
| "We have purchased LBH-589, Saha and MS-275 from you and they all worked well." |
| Jenny Sun |
| "We used the LBH-589 in our experiments. The compound is easy to use with excellent reproducibility." |
| Yu Wang, Harvard University |
| "The GDC0449 compound worked very well. The results in my hands are equally good as what's been published. Thanks for this great resource for our research." |
| Dung-Fang Lee |
| "Based on our preliminary data, I found MLN8237 and VX-680 have good effects in inhibiting Aurka-maintaining ESC self-renewal in mouse ES cells." |
| Jun 2011 Selleck Latest Catalog | ![]() |


